Latest Cytokine storm Stories

MONMOUTH JUNCTION, N.J., Nov. 16, 2012 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses such as sepsis, trauma, and burn injury, announced today that due to a loss of power for an extended period of time caused by Superstorm Sandy, the Company has been granted additional time by the Securities and Exchange Commission to file its Form 10-Q for the quarter ended September 30, 2012....

MONMOUTH JUNCTION, N.J., Sept. 24, 2012 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses such as sepsis, trauma, and burn injury, announced that, after a competitive process, the US Army Medical Research and Materiel Command has selected the Company's Phase II SBIR (Small Business Innovation Research) proposal for funding. This follows the successful completion of a previously funded...

Many patients with hypertension are treated with ACE inhibitors. These drugs block the angiotensin converting enzyme (ACE) that regulates the salt and water balance of the body and raises blood pressure. Recent studies by a research team led by Professor Ken Bernstein (Cedars-Sinai Medical Center, Los Angeles, California, USA) have, however, significantly broadened the enzyme’s known task spectrum: The enzyme also plays a key role in blood formation, renal development and male fertility. In...

MONMOUTH JUNCTION, N.J., Jan. 11, 2012 /PRNewswire/ -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, issued the following letter to shareholders. Dear Shareholders and Friends, 2011 was an outstanding year for CytoSorbents, marked by the achievement of numerous major milestones that have led to the first ever product revenue for the Company. Although modest, initial sales from our...

An analysis of lung and spleen tissue from patients who died of sepsis revealed certain biochemical, cellular and histological findings that were consistent with immunosuppression, according to a study in the December 21 issue of JAMA. "Sepsis is responsible for more than 225,000 deaths annually in the United States. Developing new therapies for sepsis has been particularly challenging, with more than 25 unsuccessful drug trials. Characterized by an initial intense inflammatory response or...

(Ivanhoe Newswire) – Normally, having the flu is little more than a nuisance. Other times, it can spark an exaggerated immune response and turn deadly. The origins of this severe immune response, called a cytokine storm, have now been traced to its source, according to this study. Cytokines are the chemical signals that drive inflammation, and cytokine storms are thought to be the cause of many of the deaths attributed to the 1918 worldwide influenza pandemic and to the more recent...

  While illnesses such as influenza are often little more than an inconvenience, sometimes they can become fatal, and now researchers at the Scripps Research Institute claim to have found out why that can happen. Writing in Friday's edition of the journal Cell, the Scripps scientists discovered the source of the severer immune-system reaction known as a "cytokine storm," which "floods the tiny air sacs of the lungs with fluid and infection-fighting cells, blocking off airways and...

MONMOUTH JUNCTION, N.J., Aug. 4, 2011 /PRNewswire/ -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it is exhibiting at the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference to be held at the Marriott Harbor Beach Conference Center in Fort Lauderdale, Florida. CytoSorbents will be exhibiting from August 15-18, 2011 in Booth #60. ATACCC is the Department of...

An international research team has identified a lung protein that appears to play a key role in smoking-related emphysema and have crafted an antibody to block its activity, Indiana University scientists reported.The research, conducted in mice, suggests that the protein, a cytokine named EMAPII, could provide a target for drugs to treat emphysema, said Irina Petrache, M.D., associate professor of medicine at the Indiana University School of Medicine. The research was posted online May 16 for...

13therapeutics, Inc. today announced that the company has received a new Small Business Innovation Research (SBIR) grant from the National Institutes of Health, for $3.0 million. This adds to the six previous grants awarded to the company for various applications of its patented anti-inflammatory peptides, for a total in NIH funding to date of $6.8 million. Wilsonville, OR (PRWEB) January 21, 2011 13therapeutics, Inc. today announced that the company has received a new Small Business...